US FDA approves Scholar Rock's muscle weakness drug
11/09/2026 22:24
US FDA approves Scholar Rock's muscle weakness drug Sept 11 (Reuters) - The U.S. Food and Drug Administration on Friday approved Scholar Rock's SRRK.O therapy to treat a rare genetic condition that causes muscle weakness.
(Reporting by Sneha S K in Bengaluru; Editing by Tasim Zahid)
Recent news on Scholar Rock Holding
See all newsBrief: Scholar Rock Reports New Employee Inducement Grants
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (Maa) To European Medicines Agency (EMA) For Treatment Of Children And Adults With Spinal Muscular Atrophy (SMA)
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up